MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Palliative and end-of-life care in Parkinson’s disease : French patients’ perceptions and knowledge

    M. Auffret, L. Cronier, G. Robert, M. Béreau, M. Giffard, M. Vérin (Rennes, France)

    Objective: (1) Assess patients' perceptions and knowledge of palliative and end-of-life care in PD; (2) evaluate (i) whether patients discuss these topics with healthcare professionals and/or…
  • 2024 International Congress

    A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.

    P. Millar Vernetti, D. Mirski, JC. Dodart, A. Wood, HJ. Yu, J. Boyd, P. Kundu, R. Setton, D. Silbersweig, E. Stern, C. Lucero, S. Gerrol, H. Kaufmann, J. Martinez (New York, USA)

    Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…
  • 2024 International Congress

    Cervical percutaneous interferential current stimulation improves cough reflex and oral residue in patients with Parkinson’s disease

    M. Nakamori, M. Toko, H. Yamada, Y. Hayashi, K. Yoshikawa, A. Hiraoka, M. Yoshikawa, T. Nagasaki, Y. Mikami, H. Maruyama (Hiroshima, Japan)

    Objective: Patients with Parkinson's disease (PD) encounter various swallowing disorders. This study aimed to assess the effects of cervical percutaneous interferential current stimulation on pharyngeal…
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: This study aimed to explore the efficacy of opicapone (OPC) 50 mg versus an extra 100 mg levodopa (L-dopa) dose to treat early wearing-off…
  • 2024 International Congress

    Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support

    M. Soileau, J. Bronstein, L. Harmer, M. Shah, R. Gupta, L. Verhagen Metman (Georgetown, USA)

    Objective: To assess the efficacy and safety of foslevodopa/foscarbidopa (LDp/CDp) in people with Parkinson’s (PwP) with and without care partner support. Background: The progression of…
  • 2024 International Congress

    WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update

    J. Adams, A. Lerner, R. Al-Rubayie, T. Kangarloo, Y. Gong, V. Khachadourian, B. Tracey, D. Volfson, R. Lazman, J. Cosman, J. Edgerton, D. Anderson, A. Best, M. Kostrzebski, P. Auinger, C. Tarolli, M. Müller, D. Stephenson, E. Dorsey (Rochester, USA)

    Objective: To evaluate longitudinal change in WATCH-PD digital measures in a remote extension study in order to maximize learnings and inform use of digital measures…
  • 2024 International Congress

    Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies

    R. Petty, V. Agarwal, J. Allison, S. Bartolomeu Pires, M. Bartlett, T. Boey, R. Croucher, H. Collins, S. Collins, E. Davies, J. Duffen, R. Ellis-Doyle, C. Gonzalez-Robles, F. Hudson, J. Inches, L. Miller, G. Mills, S. Wonnacott, T. Foltynie, C. Carroll, S. Mullin, M. Zeissler (Plymouth, United Kingdom)

    Objective: To understand successful recruitment and retention strategies for clinical research studies in Parkinson’s disease (PD) Background: Half of all clinical trials do not reach…
  • 2024 International Congress

    Preliminary Efficacy of Bilateral Intraputaminal Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 18-Month Follow-Up From a Phase 1b Study

    N. Phielipp, C. Christine, A. Merola, J. Elder, P. Larson, W. San Sebastian, M. Fiandaca, C. Urrea, M. Wisniewski, A. van Laar, A. Kells, K. Bankiewicz (Irvine, USA)

    Objective: To assess the preliminary efficacy of bilateral intraputaminal delivery of adeno-associated virus serotype 2 containing glial cell line–derived neurotrophic factor (AAV2-GDNF; AB-1005) for patients…
  • 2024 International Congress

    The Effects of Baduanjin on Fine Motor Skills in Mild and Moderate Parkinson’s Disease

    JUN. Li, KF. Li, HZ. Chen, WM. Yang (Hefei, China)

    Objective: To investigate whether Baduanjin Qigong exercise could help improve fine motor skills in patients with Parkinson's disease. Background: It is common for people with…
  • 2024 International Congress

    Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention

    T. Oosterhof, E. Mitchell, A. Ascherio, B. Bloem, K. van Dijk, B. Dijkstra, L. Kaufmann, R. Lathey, E. Macklin, A. Navangul, A. Pijpers, H. Rowbotham, R. Schneider, M. Schwarzschild, N. de Vries, A. Noyce, S. Darweesh (Nijmegen, Netherlands)

    Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…
  • « Previous Page
  • 1
  • …
  • 165
  • 166
  • 167
  • 168
  • 169
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley